Your browser doesn't support javascript.
loading
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.
Buske, C; Dreyling, M; Alvarez-Larrán, A; Apperley, J; Arcaini, L; Besson, C; Bullinger, L; Corradini, P; Giovanni Della Porta, M; Dimopoulos, M; D'Sa, S; Eich, H T; Foà, R; Ghia, P; da Silva, M G; Gribben, J; Hajek, R; Harrison, C; Heuser, M; Kiesewetter, B; Kiladjian, J J; Kröger, N; Moreau, P; Passweg, J R; Peyvandi, F; Rea, D; Ribera, J-M; Robak, T; San-Miguel, J F; Santini, V; Sanz, G; Sonneveld, P; von Lilienfeld-Toal, M; Wendtner, C; Pentheroudakis, G; Passamonti, F.
Affiliation
  • Buske C; Institute of Experimental Cancer Research, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany. Electronic address: christian.buske@uni-ulm.de.
  • Dreyling M; Department of Medicine III at LMU Hospital, Munich, Germany.
  • Alvarez-Larrán A; Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain.
  • Apperley J; Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK.
  • Arcaini L; Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Besson C; Service d'Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; UVSQ, Inserm, CESP, Villejuif, France.
  • Bullinger L; Department of Hematology, Oncology, and Tumorimmunology, Campus Virchow Klinikum, Berlin, Germany; Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Corradini P; Hematology Division, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
  • Giovanni Della Porta M; Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
  • Dimopoulos M; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
  • D'Sa S; UCLH Centre for Waldenström and Neurohaematology, University College London Hospitals NHS Foundation Trust, London, UK.
  • Eich HT; Department of Radiation Oncology, University of Muenster, Münster, Germany.
  • Foà R; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
  • Ghia P; Strategic Research Program on Chronic Lymphocytic Leukemia and Laboratory of B Cell Neoplasia, Division of Molecular Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.
  • da Silva MG; Department Of Hematology, Portuguese Institute of Oncology, Lisbon, Portugal.
  • Gribben J; Barts Cancer Institute, Queen Mary University of London, London, UK.
  • Hajek R; Department of Hematooncology, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
  • Harrison C; Clinical Director - Haematology, Haemostasis, Palliative Care, Cellular Pathology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
  • Heuser M; Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hanover, Germany.
  • Kiesewetter B; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
  • Kiladjian JJ; Université de Paris, APHP, Hôpital Saint-Louis, Centre d'Investigations Cliniques, Paris, France.
  • Kröger N; Department of Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Moreau P; Hematology Department, University Hospital Hotel-Dieu, Nantes, France.
  • Passweg JR; Hematology Division, Basel University Hospital, Basel, Switzerland.
  • Peyvandi F; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Rea D; University Medical Department of Hematology and Immunology, France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC), Hôpital Saint-Louis, Paris, France.
  • Ribera JM; Clinical Hematology Department, ICO-Hospital Germans Trias i Pujol, Josep Carreras Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
  • Robak T; Department of Hematology, Medical University of Lodz, Lodz, Poland.
  • San-Miguel JF; Clínica Universidad de Navarra (CUN), Centro de Investigación Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBERONC, Pamplona, Spain.
  • Santini V; MDS Unit, Hematology, DMSC, AOUC, University of Florence, Florence, Italy.
  • Sanz G; Hematology Department, Hospital Univesitario y Politecnico La Fe, Valencia; CIBERONC, IS Carlos III, Madrid, Spain.
  • Sonneveld P; Erasmus MC Cancer Institute, Department of Haematology, Rotterdam, The Netherlands.
  • von Lilienfeld-Toal M; Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute, Jena, Germany.
  • Wendtner C; Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany.
  • Pentheroudakis G; Scientific and Medical Division, European Society for Medical Oncology, Lugano, Switzerland.
  • Passamonti F; Department of Medicine and Surgery, University of Insubria, Varese, Italy. Electronic address: Francesco.Passamonti@asst-settelaghi.it.
ESMO Open ; 7(2): 100403, 2022 04.
Article in En | MEDLINE | ID: mdl-35272130
ABSTRACT

BACKGROUND:

The COVID-19 pandemic has created enormous challenges for the clinical management of patients with hematological malignancies (HMs), raising questions about the optimal care of this patient group.

METHODS:

This consensus manuscript aims at discussing clinical evidence and providing expert advice on statements related to the management of HMs in the COVID-19 pandemic. For this purpose, an international consortium was established including a steering committee, which prepared six working packages addressing significant clinical questions from the COVID-19 diagnosis, treatment, and mitigation strategies to specific HMs management in the pandemic. During a virtual consensus meeting, including global experts and lead by the European Society for Medical Oncology and the European Hematology Association, statements were discussed and voted upon. When a consensus could not be reached, the panel revised statements to develop consensual clinical guidance. RESULTS AND

CONCLUSION:

The expert panel agreed on 33 statements, reflecting a consensus, which will guide clinical decision making for patients with hematological neoplasms during the COVID-19 pandemic.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / COVID-19 Type of study: Guideline / Prognostic_studies Limits: Humans Language: En Journal: ESMO Open Year: 2022 Type: Article